Fintel reports that on February 25, 2026, Citizens upgraded their outlook for Iovance Biotherapeutics (NasdaqGM:IOVA) from Market Perform to Market Outperform.
Analyst Price Forecast Suggests 145.86% Upside
As of February 24, 2026, the average one-year price target for Iovance Biotherapeutics is $9.29/share. The forecasts range from a low of $2.02 to a high of $17.85. The average price target represents an increase of 145.86% from its latest reported closing price of $3.78 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Iovance Biotherapeutics is 741MM, an increase of 181.24%. The projected annual non-GAAP EPS is -2.41.
What is the Fund Sentiment?
There are 388 funds or institutions reporting positions in Iovance Biotherapeutics. This is an decrease of 42 owner(s) or 9.77% in the last quarter. Average portfolio weight of all funds dedicated to IOVA is 0.08%, an increase of 32.98%. Total shares owned by institutions increased in the last three months by 19.57% to 285,364K shares. 
The put/call ratio of IOVA is 0.15, indicating a bullish outlook.
What are Other Shareholders Doing?
Mhr Fund Management holds 28,967K shares representing 7.30% ownership of the company. No change in the last quarter.
Bank Of America holds 14,278K shares representing 3.60% ownership of the company. In its prior filing, the firm reported owning 6,279K shares , representing an increase of 56.02%. The firm increased its portfolio allocation in IOVA by 206.70% over the last quarter.
Invenomic Capital Management holds 11,960K shares representing 3.01% ownership of the company. In its prior filing, the firm reported owning 10,542K shares , representing an increase of 11.86%. The firm increased its portfolio allocation in IOVA by 37.24% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 10,464K shares representing 2.64% ownership of the company. In its prior filing, the firm reported owning 8,652K shares , representing an increase of 17.32%. The firm decreased its portfolio allocation in IOVA by 44.26% over the last quarter.
Goldman Sachs Group holds 8,608K shares representing 2.17% ownership of the company. In its prior filing, the firm reported owning 6,576K shares , representing an increase of 23.61%. The firm increased its portfolio allocation in IOVA by 65.96% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
